[LncRNA BCYRN1 regulates the miR-125a-5p/HK2 axis to influence radiosensitivity in glioma cells] [0.03%]
长链非编码RNA BCYRN1通过调控miR-125a-5p/HK2轴影响胶质瘤细胞放射敏感性
T He,Z J Li,C Y Xu et al.
T He et al.
Objective: To investigate the effect and mechanism of long non-coding RNA brain cytoplasmic RNA 1 (lncRNA BCYRN1) on the radiosensitivity of glioma cells. Methods: The human glioma cell line U87 was irradiated with X-rays at doses of 0 Gy, ...
[Establishment of pediatric neuroblastoma cell line and its resistance mechanism to lorlatinib] [0.03%]
儿童神经母细胞瘤细胞系的建立及其耐药机制研究 Lorlatinib诱导神经母细胞瘤细胞-Line 2型肺腺癌的体外和体内研究
Y N Bi,H L Feng,X F Chang et al.
Y N Bi et al.
Objective: To investigate the mechanisms underlying neuroblastoma resistance to the ALK inhibitor lorlatinib. Methods: Primary tissue was obtained from a pediatric patient diagnosed with neuroblastoma who underwent surgery at Beijing Childr...
[Lifetime risk of developing cancer in Inner Mongolia cancer registration areas] [0.03%]
内蒙古肿瘤登记地区居民终身患癌风险分析
B Yin,L Y Qiao,B Q Na et al.
B Yin et al.
Objective: Assess the cancer burden in Inner Mongolia to provide evidence for cancer prevention and control decision-making. Methods: Using cancer incidence and mortality data from 38 cancer registration areas in 2020, combined with demogra...
[A retrospective study of PD-1 monoclonal antibody combined with nab-paclitaxel plus bevacizumab in the treatment of advanced malignant melanoma] [0.03%]
帕博利珠单抗联合白蛋白结合型紫杉醇和贝伐珠单抗治疗晚期恶性黑色素瘤的回顾性研究
Y Ren,L J Zhao,Z M Wei et al.
Y Ren et al.
Objective: Advanced malignant melanoma still poses significant challenges in treatment. Combining nab-paclitaxel, bevacizumab, and immunotherapy has shown promising efficacy across various cancer types. This retrospective study aimed to ass...
[Neoadjuvant immunotherapy for resectable locally advanced colorectal cancer] [0.03%]
可切除局部晚期结直肠癌的新辅助免疫治疗
Z K Luo,Y Sun,R S Xiang et al.
Z K Luo et al.
Objective: To evaluate the efficacy and safety of resectable locally advanced colorectal cancer (LACRC) after neoadjuvant immunotherapy (IT). Methods: A retrospective analysis of the clinicopathological data of 32 patients with locally adva...
[Impact of low density lipoprotein cholesterol on the risk of gastrointestinal cancer] [0.03%]
低密度脂蛋白胆固醇与消化系统肿瘤发病风险的关联研究进展
S F Luo,X M Ma,J T Yang et al.
S F Luo et al.
Objective: To investigate the impact of different low density lipoprotein-cholesterol (LDL-C) levels on the risk of gastrointestinal cancer. Methods: A prospective cohort study was used to observe 126 050 in service and retired employees of...
[Efficacy and safety of SOX regimen combined with Pembrolizumab in the treatment of metastatic gastric cancer] [0.03%]
[SOX方案联合帕博利珠单抗治疗转移性胃癌的疗效和安全性]
W Zhao,J Yan,Y Luo et al.
W Zhao et al.
Objective: To investigate the clinical efficacy, toxicity and prognosis of SOX regimen (Oxaliplatin plus S-1) combined with Pabolizumab in the treatment of patients with metastatic gastric cancer. Methods: The clinical data of 107 patients ...
[Non-invasive and high-precision identification of gastric precancerous lesions based on SERS and machine learning] [0.03%]
基于拉曼光谱和机器学习的胃癌前病变高精度无创识别方法研究
L M Li,Q S Zhu,Z Wu et al.
L M Li et al.
Objective: To construct a non-invasive detection platform based on surface enhanced Raman spectroscopy (SERS) combined with machine learning, achieving high-precision recognition of precancerous lesions of gastric cancer. Method: Serum samp...
[Comparison of the efficacy and safety of 36 000 IU vs. 40 000 IU recombinant human erythropoietin for the treatment of cancer-related anemia: a multicenter, open-label, randomized controlled trial] [0.03%]
36000 U与40000 U重组人促红素治疗肿瘤相关性贫血的疗效和安全性比较多中心开放标签随机对照试验
Y F Jia,J Xia,X M Liu et al.
Y F Jia et al.
Objective: To investigate the efficacy and safety of 36 000 IU recombinant human erythropoietin (rhEPO) in the treatment of cancer-related anemia (CRA) and to evaluate whether 36 000 IU rhEPO can serve as a rational "reduced-dose alternativ...
Randomized Controlled Trial
Zhonghua zhong liu za zhi [Chinese journal of oncology]. 2026 Apr 23;48(4):525-535. DOI:10.3760/cma.j.cn112152-20250619-00280 2026
[Analysis and prediction of liver cancer mortality trends in Qidong City of China, 1972-2024] [0.03%]
中国启东市肝癌死亡率分析及1972-2024年预测
Y S Chen,J Zhu,Y H Zhang et al.
Y S Chen et al.
Objective: To analyze the mortality trends of liver cancer in the general population of Qidong City, Jiangsu Province from 1972 to 2024, and to predict the mortality burden from 2025 to 2034, providing a basis for liver cancer prevention an...